Drug Interactions between albendazole and carbamazepine
This report displays the potential drug interactions for the following 2 drugs:
- albendazole
- carbamazepine
Interactions between your drugs
carBAMazepine albendazole
Applies to: carbamazepine and albendazole
MONITOR: Coadministration with anticonvulsant drugs such as carbamazepine, phenytoin, phenobarbital, and primidone may decrease the plasma concentrations and half-life of the active metabolite of albendazole, albendazole sulfoxide. The mechanism is unknown, but induction of hepatic metabolism by these anticonvulsant drugs has been proposed. In a study of 32 adult patients with neurocysticercosis receiving albendazole 7.5 mg/kg every 12 hours for 8 days, mean systemic exposure (AUC) on day 8 for the (+) enantiomer of albendazole sulfoxide in patients on concomitant anticonvulsant therapy with carbamazepine (n=9), phenytoin (n=9) or phenobarbital (n=5) was 49%, 66% and 61% lower, respectively, than in control patients who were not on anticonvulsants (n=9), while mean peak plasma concentration (Cmax) was 50%, 63% and 63% lower, respectively. For the (-) enantiomer of albendazole sulfoxide, mean AUC on day 8 was 67% 78% and 72% lower, and mean Cmax was 50%, 70% and 50% lower in the carbamazepine, phenytoin and phenobarbital groups, respectively, compared to the control group. Mean half-life was 3.1 to 4.2 hours shorter for (+) albendazole sulfoxide and 2.2 to 2.4 hours shorter for (-) albendazole sulfoxide in patients receiving anticonvulsants than in controls. The clinical impact of this interaction is expected to be minimal in the treatment of intestinal infections but may be increased when albendazole is used for systemic helminthic diseases such as neurocysticercosis. However, the clinical relevance of plasma concentrations of albendazole and albendazole sulfoxide during treatment of neurocysticercosis has not been established. In case reports and studies in the medical literature of patients with neurocysticercosis, albendazole was generally given without dosage adjustment in the presence of anticonvulsants such as carbamazepine, phenytoin and phenobarbital, and there have been no specific reports of therapeutic failure of albendazole attributed to suspected interaction with these anticonvulsants.
MANAGEMENT: Caution and monitoring for altered clinical efficacy are recommended if albendazole is used concomitantly with anticonvulsant drugs such as carbamazepine, phenytoin, phenobarbital, or primidone in patients treated for systemic helminthic infections. Dose adjustments or alternative treatments may be required if an interaction is suspected.
References (5)
- Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM (2002) "Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis." Ther Drug Monit, 24, p. 338-45
- Cerner Multum, Inc. "Australian Product Information."
- Corti N, Heck A, Rentsch K, et al. (2009) "Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers." Eur J Clin Pharmacol, 65, p. 999-1006
- Romo ML, Carpio A, Kelvin EA (2014) "Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: a reason for the variable efficacy of albendazole and praziquantel?" J Clin Pharmacol, 54, p. 361-7
- Pawluk SA, Roels CA, Wilby KJ, Ensom MHH (2015) "A review of pharmacokinetic drug–drug interactions with the anthelmintic medications albendazole and mebendazole." Clin Pharmacokinet, 54, p. 371-83
Drug and food interactions
carBAMazepine food
Applies to: carbamazepine
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of carbamazepine. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
In a small, randomized, crossover study, the administration of carbamazepine with grapefruit juice (compared to water) increased plasma drug concentrations by approximately 40%. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.
MANAGEMENT: Patients receiving carbamazepine should be advised to avoid or limit consumption of alcohol. Given the drug's narrow therapeutic index, patients receiving carbamazepine therapy should preferably avoid the regular consumption of grapefruits and grapefruit juice to prevent any undue fluctuations in plasma drug levels. Patients should be advised to report signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia) to their physicians.
References (3)
- (2002) "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals
- Garg SK, Kumar N, Bhargava VK, Prabhakar SK (1998) "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther, 64, p. 286-8
- Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR (2000) "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther, 68, p. 468-77
albendazole food
Applies to: albendazole
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of albendazole, which is rapidly converted by hepatocytes and intestinal mucosal cells into the active metabolite, albendazole sulfoxide (ABZSX), following absorption. The proposed mechanism is stimulation of gastric acid secretion, as the absorption of albendazole is thought to be pH-dependent. According to the product labeling, plasma concentrations of ABZSX are up to 5-fold higher on average when albendazole is administered with a fatty meal (fat content approximately 40 g) compared to administration in the fasted state. In one study of six healthy male volunteers, administration of a single 10 mg/kg oral dose of albendazole in combination with a high-fat meal (57 g fat, 1399 kcal) increased the mean ABZSX peak plasma concentration (Cmax) and systemic exposure (AUC) by 6.5- and 9.4-fold, respectively, and delayed the time to reach Cmax (Tmax) from 2.5 to 5.3 hours compared to administration in the fasted state with water. The elimination half-life was not affected.
MONITOR: Grapefruit juice may increase the oral bioavailability of albendazole, which is rapidly converted by hepatocytes and intestinal mucosal cells into the active metabolite, albendazole sulfoxide (ABZSX), following absorption. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In six healthy male volunteers, administration of a single 10 mg/kg oral dose of albendazole in combination with 250 mL of double-strength grapefruit juice increased the mean ABZSX peak plasma concentration (Cmax) and systemic exposure (AUC) by 3.2- and 3.1-fold, respectively, compared to administration with water. However, because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: To ensure maximal oral absorption, albendazole should be taken with food. Grapefruit juice may also enhance the oral bioavailability of albendazole.
References (3)
- Awadzi K, Hero M, Opoku NO, Buttner DW, Coventry PA, Prime MA, Orme ML, Edwards G (1994) "The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics." Trop Med Parasitol, 45, p. 203-8
- (2001) "Product Information. Albenza (albendazole)." SmithKline Beecham
- Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA (2002) "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg, 66, p. 260-3
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.